Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system

Citation
J. Zujewski et al., Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system, BREAST CA R, 3(1), 2001, pp. 66-75
Citations number
50
Language
INGLESE
art.tipo
Review
Categorie Soggetti
Oncology
Journal title
BREAST CANCER RESEARCH
ISSN journal
1465-542X → ACNP
Volume
3
Issue
1
Year of publication
2001
Pages
66 - 75
Database
ISI
SICI code
1465-542X(2001)3:1<66:TGFANG>2.0.ZU;2-V
Abstract
Using a carcinogen-initiated rat model of mammary tumorigenesis, we tested the hypothesis that transforming growth factor (TGF)-betas are useful bioma rkers of chemopreventive efficacy in the breast. The chemopreventive agents tested were tamoxifen and the retinoids 9-cis-retinoic acid (9cRA) and N-( 4-hydroxyphenyl) retinamide (4-HPR), because both antiestrogens and retinoi ds have previously been shown to upregulate TGF-betas in vitro. Despite dem onstrable chemopreventive efficacy in this model, none of these agents, alo ne or in combination, had any significant impact on the expression of TGF-b etas in the mammary ductal epithelium or periductal stroma as determined by immunohistochemistry. These data suggest that TGF-betas are not likely to be useful biomarkers of chemopreventive efficacy in a clinical setting.